Objective: We evaluated the cerebrospinal fluid (CSF) cytokine profile and magnetic resonance imaging (MRI) findings in systemic lupus erythematosus (SLE) patients with central nervous system (CNS) involvement. Methods: Consecutive SLE patients followed at the rheumatology unit were enrolled into this study. Neurologically asymptomatic controls were matched for age and sex and recruited during myelography. SLE patients were assessed for disease activity (Systemic Lupus Erythematosus Disease Activity Index; SLEDAI) and cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SDI). All subjects underwent MRI scans and blood and CSF withdrawal. Immunoglobulin G (IgG) and albumin were measured by nephelometry and link indexes were calculated according to the literature. Interleukin (IL)-12 p40/p70, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and IL-10 were measured by enzyme-linked immunosorbent assay. Results: We included 20 SLE patients (18 women, mean age 30.2 ± 9.2 years, range 19-45) with CNS manifestations. Increased IL-12 p40/p70, IFN-γ, TNF-α, and IL-10 CSF levels were observed in SLE patients. Mild pleocytosis was observed in 8 (66%) SLE patients and intrathecal production of IgG was observed in 2 (10%) SLE patients. Three (15%) SLE patients had demyelinating lesions, 5 (25%) patients had cerebral atrophy, and 12 (60%) patients had ischemic lesions on MRI. We observed that the cerebral lesion count was associated with CNS manifestations and SDI scores. We observed a significant cerebral volume reduction in SLE patients compared to controls (p < 0.001). Moreover, a direct correlation between cerebral volume reduction and CSF IFN-γ levels was observed (r = 0.5, p = 0.01). Conclusions: IL-12 p40/p70, IFN-γ, TNF-α, and IL-10 CSF levels were increased in SLE patients with CNS manifestations, but only IFN-γ was associated with a cerebral volume reduction in SLE, suggesting an immunological basis for global atrophy in SLE.

1.
Hanly JG, Su L, Farewell V, McCurdy G, Fougere L, Thompson K: Prospective study of neuropsychiatric events in systemic lupus erythematosus. J Rheumatol 2009;36:1449-1459.
2.
Hanly JG: Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014;10:338-347.
3.
Postal M, Costallat LT, Appenzeller S: Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs 2011;25:721-736.
4.
Trysberg E, Carlsten H, Tarkowski A: Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000;9:498-503.
5.
Appenzeller S, Pike GB, Clarke AE: Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2008;34:361-366.
6.
Winfield JB, Shaw M, Silverman LM, Eisenberg RA, Wilson HA 3rd, Koffler D: Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction. Am J Med 1983;74:837-844.
7.
Hirohata S, Hirose S, Miyamoto T: Cerebrospinal Fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus: their use as estimates of central nervous system disease activity. Arch Intern Med 1985;145:1843-1846.
8.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
9.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
10.
Wechsler D: The Measurement of Adult Intelligence. Baltimore, Williams & Wilkins, 1939.
11.
Ryan JJ, Schnakenberg-Ott SD: Scoring reliability on the Wechsler Adult Intelligence Scale Third Edition (WAIS-III). Assessment 2003;10:151-159.
12.
Woods SP, Delis DC, Scott JC, Kramer JH, Holdnack JA: The California Verbal Learning Test - second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol 2006;21:413-420.
13.
Lezak JAMD: Neuropsychological Assessment. New York, Oxford University Press, 1995.
14.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI: a disease activity index for lupus patients - the Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640.
15.
Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez-Guerrero J, Snaith M, Sturfelt G: The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-813.
16.
Link H, Tibbling G: Principles of albumin and IgG analyses in neurological disorders. 3. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977;37:397-401.
17.
Keir G, Luxton RW, Thompson EJ: Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem 1990;27:436-443.
18.
Harris EN, Gharavi AE, Patel SP, Hughes GR: Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-222.
19.
Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-1190.
20.
Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F: Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005;52:2783-2789.
21.
Appenzeller S, Bonilha L, Rio PA, Min Li L, Costallat LT, Cendes F: Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 2007;34:694-701.
22.
Lapa AT, Postal M, Sinicato NA, Ferreira WG, Bellini BS, Fernandes PT, Rittner L, Marini R, Cendes F, Appenzeller S: Reduction of cerebral and corpus callosum volumes in childhood-onset systemic lupus erythematosus: a volumetric magnetic resonance imaging analysis. Arthritis Rheumatol 2016, DOI: 10.1002/art.39680.
23.
Sarbu N, Alobeidi F, Toledano P, Espinosa G, Giles I, Rahman A, Yousry T, Capurro S, Jäger R, Cervera R, Bargalló N: Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev 2015;14:153-159.
24.
Appenzeller S, Vasconcelos Faria A, Li LM, Costallat LT, Cendes F: Quantitative magnetic resonance imaging analyses and clinical significance of hyperintense white matter lesions in systemic lupus erythematosus patients. Ann Neurol 2008;64:635-643.
25.
Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata S, Minota S: IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus 2016;25:997-1003.
26.
Ichinose K, Arima K, Umeda M, Fukui S, Nishino A, Nakashima Y, et al: Predictors of clinical outcomes in patients with neuropsychiatric systemic lupus erythematosus. Cytokine 2016;79:31-37.
27.
Svenungsson E, Andersson M, Brundin L, van Vollenhoven R, Khademi M, Tarkowski A, Greitz D, Dahlström M, Lundberg I, Klareskog L, Olsson T: Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001;60:372-379.
28.
McAdams RM, Juul SE: The role of cytokines and inflammatory cells in perinatal brain injury. Neurol Res Int 2012;2012:561494.
29.
George-Chandy A, Trysberg E, Eriksson K: Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008;10:R97.
30.
Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narváez A, Dávila-Maldonado L, Atisha-Fregoso Y, Llorente L, Sánchez-Guerrero J: Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007;56:1242-1250.
31.
Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, Hashimoto H: Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999;116:169-173.
32.
Goleva E, Li LB, Leung DY: IFN-gamma reverses IL-2- and IL-4-mediated T-cell steroid resistance. Am J Respir Cell Mol Biol 2009;40:223-230.
33.
Jefferson AL, Massaro JM, Wolf PA, Seshadri S, Au R, Vasan RS, Larson MG, Meigs JB, Keaney JF Jr, Lipinska I, Kathiresan S, Benjamin EJ, DeCarli C: Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007;68:1032-1038.
34.
Hartung HP, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners KH, Toyka KV: Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 1995;45:S22-S32.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.